Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist

Bone

Volumn 37, Issue 4, 2005, Pages 555-562

  Toyoda, Hiromitsu ^a   Terai, Hidetomi ^a   Sasaoka, Ryuichi ^a   Oda, Kazunori ^b   Takaoka, Kunio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Biomaterials; Bone metabolism; Bone mineral density; Bone morphogenetic proteins; Bone volume

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; COPOLYMER; DIOXANE DERIVATIVE; MACROGOL; POLYLACTIC ACID; PROSTAGLANDIN E 4 RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RECOMBINANT OSTEOGENIC PROTEIN 1; UNCLASSIFIED DRUG;

AGONIST; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY OSSICLE; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DUAL ENERGY X RAY ABSORPTIOMETRY; MALE; MOUSE; MUSCLE; NONHUMAN; RECEPTOR SENSITIVITY; TISSUE FIXATION; TISSUE SECTION;

ALKALINE PHOSPHATASE; ANIMALS; BODY WEIGHT; BONE MORPHOGENETIC PROTEINS; HUMANS; MALE; MICE; MICE, INBRED ICR; OSTEOCALCIN; RECEPTORS, PROSTAGLANDIN E; RECOMBINANT PROTEINS; SULFHYDRYL COMPOUNDS; THIOPHENES;

EID: 24944446761     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.04.042     Document Type: Article

References (40)

1. M.R. Urist Bone: formation by autoinduction Science 150 1965 893 899
2. J.M. Wozney, V. Rosen, A.J. Celeste, L.M. Mitsock, M.J. Whitters, and R.W. Kriz Novel regulators of bone formation: molecular clones and activities Science 242 1988 1528 1534
3. S.D. Boden, T.A. Zdeblick, H.S. Sandhu, and S.E. Heim The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report Spine 25 2000 376 381
4. S.D. Boden, J. Kang, H. Sandhu, and J.G. Heller Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies Spine 27 2002 2662 2673
5. J.K. Burkus, M.F. Gornet, C.A. Dickman, and T.A. Zdeblick Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages J. Spinal Disord. Tech. 15 2002 337 349
6. R. Johnsson, B. Stromqvist, and P. Aspenberg Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion Spine 27 2002 2654 2661
7. S. Miyamoto, K. Takaoka, T. Okada, H. Yoshikawa, J. Hashimoto, and S. Suzuki Evaluation of polylactic acid homopolymers as carriers for bone morphogenetic protein Clin. Orthop. 278 1992 274 285
8. N. Murakami, N. Saito, H. Horiuchi, T. Okada, K. Nozaki, and K. Takaoka Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer J. Biomed. Mater. Res. 62 2002 169 174
9. N. Saito, T. Okada, H. Horiuchi, N. Murakami, J. Takahashi, and M. Nawata A biodegradable polymer as a cytokine delivery system for inducing bone formation Nat. Biotechnol. 19 2001 332 335
10. N. Saito, T. Okada, H. Horiuchi, H. Ota, J. Takahashi, and N. Murakami Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers Bone 32 2003 381 386
11. H. Horiuchi, N. Saito, T. Kinoshita, S. Wakabayashi, N. Yotsumoto, and K. Takaoka Effect of phosphodiesterase inhibitor-4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2 Bone 30 2002 589 593
12. T. Kinoshita, S. Kobayashi, S. Ebara, Y. Yoshimura, H. Horiuchi, and T. Tsutsumimoto Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice Bone 27 2000 811 817
13. R. Sasaoka, H. Terai, H. Toyoda, Y. Imai, R. Sugama, and K. Takaoka A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2 Biochem. Biophys. Res. Commun. 318 2004 704 709
14. P. Bergmann, and A. Schoutens Prostaglandins and bone Bone 16 1995 485 488
15. H. Kawaguchi, C.C. Pilbeam, J.R. Harrison, and L.G. Raisz The role of prostaglandins in the regulation of bone metabolism Clin. Orthop. 313 1995 36 46
16. L.G. Raisz, J.Y. Vanderhoek, H.A. Simmons, B.E. Kream, and K.C. Nicolaou Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin Prostaglandins 17 1979 905 914
17. W.S.S. Jee, K. Ueno, Y.P. Deng, and D.M. Woodbury The effects of prostaglandin E2 in growing rats: increased metaphyseal hard tissue and cortico-endosteal bone formation Calcif. Tissue Int. 37 1985 148 157
18. K. Sone, M. Tashiro, T. Fujinaga, T. Tomomasa, K. Tokugawa, and T. Kuroume Long-term low-dose prostaglandin E1 administration J. Pediatr. 97 1980 866 867
19. R.S. Yang, T.K. Liu, and S.Y. Lin-Shiau Increased bone growth by local prostaglandin E2 in rats Calcif. Tissue Int. 52 1993 57 61
20. R.A. Coleman, I. Kennedy, and R.L. Sheldrick New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors Adv. Prostaglandin Thromboxane Leukotriene Res. 17 1987 467 470
21. R.A. Coleman, W.L. Smith, and S. Narumia Classification of prostanoid receptors: properties distribution, and structure of the receptors and their subtypes Pharmacol. Rev. 46 1994 205 229
22. H. Hizaki, E. Segi, Y. Sugimoto, M. Hirose, T. Saji, and F. Ushikubi Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2) Proc. Natl. Acad. Sci. U. S. A. 96 1999 10501 10506
23. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties, and functions Physiology 79 1999 1193 1226
24. E. Segi, Y. Sugimoto, A. Yamasaki, Y. Aze, H. Oida, and T. Nishimura Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice Biochem. Biophys. Res. Commun. 246 1998 7 12
25. F. Ushikubi, E. Segi, Y. Sugimoto, T. Murata, T. Matsuoka, and T. Kobayashi Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 Nature 395 1998 281 284
26. Y. Sakuma, K. Tanaka, M. Suda, A. Yasoda, K. Natsui, and I. Tanaka Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide J. Bone Miner. Res. 15 2000 218 227
27. T. Suzawa, C. Miyaura, M. Inada, T. Maruyama, Y. Sugimoto, and F. Ushikubi The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs Endocrinology 14 2000 1554 1559
28. C. Miyaura, M. Inada, T. Suzawa, Y. Sugimoto, F. Ushikubi, and A. Ichikawa Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice J. Biol. Chem. 275 2000 19819 19823
29. X. Li, C.C. Pilbeam, L. Pan, R.M. Breyer, and L.G. Raisz Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice Bone 30 2002 567 573
30. K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, and T. Katayama Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation Proc. Natl. Acad. Sci. U. S. A. 99 2002 4580 4585
31. M. Machwate, S. Harada, C.T. Leu, G. Seedor, M. Labelle, and M. Gallant Prostaglandin receptor EP (4) mediates the bone anabolic effects of PGE (2) Mol. Pharmacol. 60 2001 36 41
32. D. Shamir, S. Keila, and M. Weinreb A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro Bone 34 2004 157 162
33. M. Tanaka, A. Sakai, S. Uchida, S. Tanaka, M. Nagashima, and T. Katayama Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats Bone 34 2004 940 948
34. N. Murakami, N. Saito, J. Takahashi, H. Ota, H. Horiuchi, and M. Nawata Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier Biomaterials 24 2003 2153 2159
35. M. Suda, K. Tanaka, K. Natsui, T. Usui, I. Tanaka, and M. Fukushima Prostaglandin E receptor subtypes in mouse osteoblastic cell line Endocrinology 137 1996 1698 1705
36. M. Weinreb, A. Grosskopf, and N. Shir The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype Am. J. Physiol. 276 1999 376 383
37. D. Shamir, S. Keila, and M. Weinreb A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro Bone 34 2004 157 162
38. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.Y. Reginster Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 44 2001 1434 1441
39. X. Zhang, E.M. Schwarz, D.A. Young, J.E. Puzas, R.N. Rosier, and R.J. O'Keefe Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair J. Clin. Invest. 109 2002 1405 1415
40. D. Chikazu, X. Li, H. Kawaguchi, Y. Sakuma, O.S. Voznesensky, and D.J. Adams Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo J. Bone Miner. Res. 17 2002 1430 1440